Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
Pharmaceuticals, Free Full-Text
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
Ibrutinib Single-handedly Impacts Immune Environment in Metastatic PDAC
Pharmaceutics, Free Full-Text
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies - Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jérôme Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel, 2022
Cancers, Free Full-Text
Frontiers Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
de
por adulto (o preço varia de acordo com o tamanho do grupo)
